CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer

  • Authors:
    • Riki Okita
    • Toshiaki Saeki
    • Shigemitsu Takashima
    • Yoshiyuki Yamaguchi
    • Tetsuya Toge
  • View Affiliations

  • Published online on: November 1, 2005     https://doi.org/10.3892/or.14.5.1269
  • Pages: 1269-1273
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

It is well known that immunosuppression may contribute to the progression and chemotherapy-resistance of cancer. Recent studies have demonstrated that lymphocytes with the phenotype of CD4+CD25+ regulatory T cells (T-regs) contribute to immune dysfunction in cancer patients, and a relative increase in CD4+CD25+ regulatory T cells is related to immunosuppression and tumor progression in patients with some malignancies. In the present study, we evaluated the prevalence of T-regs in the peripheral blood of patients with breast cancer and non-small cell lung cancer. The phenotype of lymphocyte CD4+CD25+ cells was analyzed in peripheral blood of patients with breast cancer (n=22) and non-small cell lung cancer (NSCLC) (n=17). The population of CD4+CD25+ cells in CD3+ and CD4+ cells was evaluated by flow cytometric analysis with triple-color staining. Patients with breast cancer did not have a higher percentage of CD4+CD25+ cells in the total CD3+ and CD4+ cells in their peripheral blood than healthy volunteers. In contrast, patients with recurrent NSCLC had significantly higher percentages of CD4+CD25+ cells in CD3+ (47.6%) and CD4+ (71.0%) than healthy volunteers (n=10) who had CD4+CD25+ cells in CD3+ (33.7%, p=0.02) and CD4+ (52.2%, p<0.03). The population of CD4+CD25+ T-regs in the peripheral blood of patients with non-small cell lung cancer was significantly higher than that in healthy volunteers but not in breast cancer patients. These findings suggest that the use of T-reg-targeted immunomodulatory therapy may be a more effective strategy for patients with non-small cell lung cancer than for those with breast cancer.

Related Articles

Journal Cover

November 2005
Volume 14 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Okita R, Saeki T, Takashima S, Yamaguchi Y and Toge T: CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 14: 1269-1273, 2005
APA
Okita, R., Saeki, T., Takashima, S., Yamaguchi, Y., & Toge, T. (2005). CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncology Reports, 14, 1269-1273. https://doi.org/10.3892/or.14.5.1269
MLA
Okita, R., Saeki, T., Takashima, S., Yamaguchi, Y., Toge, T."CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer". Oncology Reports 14.5 (2005): 1269-1273.
Chicago
Okita, R., Saeki, T., Takashima, S., Yamaguchi, Y., Toge, T."CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer". Oncology Reports 14, no. 5 (2005): 1269-1273. https://doi.org/10.3892/or.14.5.1269